Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.53 USD | -2.71% | -0.96% | -6.40% |
Apr. 24 | Earnings Flash (CLB) CORE LABORATORIES Reports Q1 Revenue $129.6M, vs. Street Est of $124.5M | MT |
Apr. 24 | Earnings Flash (CLB) CORE LABORATORIES Reports Q1 EPS $0.19, vs. Street Est of $0.16 | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Business Support Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.40% | 796M | B+ | ||
+12.99% | 16.5B | A | ||
0.00% | 6.73B | - | - | |
-11.83% | 2.85B | B+ | ||
-13.46% | 2.59B | - | ||
-33.87% | 1.63B | - | - | |
+3.80% | 1.16B | - | ||
-10.58% | 1.01B | - | ||
-7.74% | 870M | - | ||
-10.16% | 787M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLB Stock
- Ratings Core Laboratories Inc.